Business Wire

“Never Give Up”, Usain Bolt and Colin Jackson on Records, PUMA Family, and Future

Share

Global Sports company PUMA announces an interview with the fastest man in the world, Usain Bolt, and an iconic sprint and hurdling athlete, Colin Jackson, to celebrate the 20th anniversary between PUMA and Bolt this July.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230720866386/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The dynamic conversation between Usain Bolt and Colin Jackson provides an engaging glimpse into the life of a sporting legend. (Photo: Business Wire)

Link to the full video: HERE.

Reflecting on his remarkable journey, Bolt expresses his deep connection with PUMA, stating, "This brand has always been my choice. We've become a family, doing incredible work together. I'm proud to be a part of it." Reflecting on his early days as an aspiring athlete, Bolt shares his excitement upon receiving his first PUMA kit, describing the moment as a dream come true.

As the conversation turns to Bolt's record-breaking accomplishments, the sprinter emphasizes that his focus was always on winning medals rather than chasing records. He attributes his success not only to his exceptional performances but also to his magnetic personality, which won over fans worldwide.

The dynamic conversation between Usain Bolt and Colin Jackson provides an engaging glimpse into the life of a sporting legend. Their discussion on records, partnership, and the thrill of athletics captivated audiences, highlighting Bolt's extraordinary achievements and his passion for the sport.

Photos: HERE.

PUMA

PUMA is one of the world’s leading sports brands, designing, developing, selling and marketing footwear, apparel and accessories. For 75 years, PUMA has relentlessly pushed sport and culture forward by creating fast products for the world’s fastest athletes. PUMA offers performance and sport-inspired lifestyle products in categories such as Football, Running and Training, Basketball, Golf, and Motorsports. It collaborates with renowned designers and brands to bring sport influences into street culture and fashion. The PUMA Group owns the brands PUMA, Cobra Golf and stichd. The company distributes its products in more than 120 countries, employs about 20,000 people worldwide, and is headquartered in Herzogenaurach/Germany.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact:
PUMA
Gudrun Cämmerer
Teamhead Global Brand PR
gudrun.caemmerer@puma.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SBC Medical Group Enters the Thai Market through Partnership with BLEZ14.11.2025 14:47:00 EET | Press release

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced that it has entered into a Consulting Agreement with BLEZ ASIA Co., Ltd. (Headquarters: Bangkok, Thailand; CEO: Naoki Iida; “BLEZ”), which operates more than 20 pharmacies and clinics in Thailand and is widely trusted by both Japanese expatriates and local patients. The partnership is a key component of SBC’s broader Asia strategy and represents a significant step toward full-scale entry into the rapidly growing Thai aesthetic medicine market. Under the agreement, SBC will provide comprehensive management support to a new clinic focused primarily on dermatological treatments such as pigmentation and spot removal, which BLEZ is preparing to open in Bangkok. SBC will advise on clinical protocol development, aligned with SBC’s quality standards, and assist in selecting me

SBC Medical Group Holdings Announces Third Quarter 2025 Financial Results14.11.2025 14:00:00 EET | Press release

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced its financial results for the third quarter of fiscal year 2025 (three months ended September 30, 2025) and for the third quarter cumulative of fiscal year 2025 (Year-to-Date 2025, nine months ended September 30, 2025) Third Quarter 2025 Highlights Total revenues were $43 million, representing an 18% year-over-year decrease. Income from operations was $16 million, representing a 15% year-over-year increase. Net Income attributable to SBC Medical Group was $13 million , representing an 353% year-over-year increase. Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.12 for the three months ended September 30, 2025, compared to $0.03 in the same period of 2024. EBITDA1, which

Ant Group Chairman Eric Jing Outlines Strategy for Inclusive AI, Collaboration on Tokenised Settlement14.11.2025 12:15:00 EET | Press release

Eric Jing, Chairman of Ant Group, said the company's focus is on putting new payment and operation tools powered by AI and tokenisation technology in the hands of SMEs, to fully embrace the next wave of global productivity revolution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251114239737/en/ Ant Group Chairman Eric Jing (second from right) shares insights during a panel discussion titled “Steering the Global Future” during the Singapore FinTech Festival on November 14, 2025. “We are passionate about using frontier technology to support SMEs and the use of AI will really uplift inclusion,” Jing said during a panel discussion titled “Steering the Global Future” during the Singapore FinTech Festival on November 14, 2025. Jing was joined by Agustín Carstens, Former General Manager, Bank for International Settlements (BIS); Ravi Menon, Chairman of the Board of Directors, Global Finance & Technology Network (GFTN); Ambassado

Allianz Achieves Record Results and Expects a Full-Year Operating Profit of at Least 17 Billion Euros14.11.2025 08:16:00 EET | Press release

3Q 2025 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251113803211/en/ Oliver Bäte, Chief Executive Officer of Allianz SE Double-digit growth in operating profit and shareholders’ core net incomeTotal business volume rises 5.21 percent with contributions from all segments Operating profit increases 12.6 percent to 4.4 billion euros, with particular strong contribution from the Property-Casualty segment Shareholders’ core net income advances by 12.7 percent and reaches 2.9 billion euros 9M 2025 Continued strong and diversified growth across our businessesand record operating profitTotal business volume rises 8.5 1 percent and reaches 141.2 billion euros with contributions from all segments Operating profit increases 10.4 percent to 13.1 billion euros, our highest nine-month operating profit ever, reaching 82 percent of our full-year outlook midpoint Shareholders’ core net income advances 10.5 percent to 8.4 billion euros. Ad

Galderma Completes Successful Placement of CHF 175 Million Bond14.11.2025 08:00:00 EET | Press release

NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR REGULATION. Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the successful placement of a single-tranche CHF 175 million Swiss franc-denominated bond. The bond has a maturity of 5 years and carries a fixed-rate annual coupon of 0.9425%. Net proceeds from the transaction will be used to partially refinance Galderma’s existing bank term loan issued at its initial public offering (IPO) in March 2024, as well as for general corporate purposes. This marks the company’s third CHF-bond issuance since listing. The new bond will be listed on the SIX Swiss Exchange, with the settlement date expected on December 10, 2025. BNP Paribas and UBS jointly led the transaction. Galderma is rated BBB (stable outlook) by Fitch. The same rating is also expected to be assigned to the new bond. The successful issuance is leverage-ne

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye